157023-34-2Relevant articles and documents
N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
-
, (2008/06/13)
Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
Discovery of diaminobutane derivatives as Ca(2+)-permeable AMPA receptor antagonists.
Yoneda, Yoshiyuki,Mimura, Tetuya,Kawagoe, Keiichi,Yasukouchi, Takanori,Tatematu, Toshiaki,Ito, Masayuki,Saito, Masaki,Sugimura, Masunobu,Kito, Fusako,Kawajiri, Shinichi
, p. 1347 - 1359 (2007/10/03)
We designed and synthesized a series of the polyamine derivatives as potent Ca(2+)-permeable AMPA receptor antagonists. In the course of this study, we found that the polyamine derivatives exhibited strong hypotensive activity which was undesirable activity for neuroprotective agents. Therefore, we tried to find non-hypotensive antagonists by structural modification of such compounds. Through this derivatization, we obtained the diamine compounds having desired profiles. Especially, compound 8f, which was non-hypotensive and potent Ca(2+)-permeable AMPA receptor antagonist, showed neuroprotective effects in transient global ischemia models in gerbils.
SRC kinase inhibitor compounds
-
, (2008/06/13)
Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of proteins tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.